SCHEMBL12162722

SCHEMBL12162722

CC(C)(C)c1cc(Cl)c(Cl)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLRA3 O75311 1/20 0.44
▸ GLRB P48167 1/20 0.44
▸ AKR1C2 P52895 2/20 0.42
▸ AKR1C1 Q04828 2/20 0.42
▸ TSHR P16473 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ DAO P14920 1/20 0.41
▸ AKR1C4 P17516 1/20 0.39
▸ AKR1C3 P42330 1/20 0.39
▸ HTT P42858 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24330214 0.83 SMN1; SMN2 (0.38) GLRA3GLRBAKR1C2AKR1C1POLB
SCHEMBL16117701 0.82 L3MBTL1 (0.42) GLRA3GLRBALDH1A1TP53SMN1; SMN2
SCHEMBL7920629 0.79 ASPH (0.50) AKR1C2AKR1C1TSHRPOLBALDH1A1
SCHEMBL13222559 0.79 KDM4E (0.43) POLBALDH1A1TP53SMN1; SMN2CASP1
SCHEMBL12162731 0.79 GAA (0.47) ALDH1A1SMN1; SMN2HTTCA12CA1
SCHEMBL14994077 0.78 SMN1; SMN2 (0.59) TSHRALDH1A1TP53SMN1; SMN2CASP1
SCHEMBL13763265 0.77 POLB (0.47) GLRA3GLRBAKR1C2AKR1C1TSHR
SCHEMBL1154451 0.77 TSHR (0.59) AKR1C2AKR1C1TSHRPOLBALDH1A1
SCHEMBL13145679 0.76 ALDH1A1 (0.57) GLRA3GLRBAKR1C2AKR1C1TSHR
SCHEMBL5462977 0.76 TSHR (0.34) AKR1C2AKR1C1TSHRPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445527-B2 Organic compounds and their uses NOVARTIS AG (CH) 2013-05-21 — — US disclosed
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-09-13 — — US disclosed
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 — — US disclosed
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 — — US disclosed
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 GLRA3 3599/4885GLRB 3421/4885AKR1C2 427/4885
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 GLRA3 3599/4885GLRB 3421/4885AKR1C2 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback